Menu Search
Equities

Hoya Corp

HYB:DUS

Hoya Corp

Actions
  • Price (EUR)118.85
  • Today's Change-0.40 / -0.34%
  • Shares traded10.00
  • 1 Year change+16.46%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hoya Corp is a Japan-based company mainly engaged in the manufacture and sale of healthcare-related products, medical-related products, electronics-related products and image-related products. The Company operates in three business segments. The Life Care segment provides healthcare-related products and medical-related products including eyeglass lenses and contact lenses, endoscopes, treatment tools, intraocular lenses, artificial bones and metal orthopedic implants. The Information and Communications segment provides electronics-related products and video-related products including mask blanks and photomasks for semiconductors, liquid crystal masks, glass substrates for hard disks, optical lenses, optical glass materials and various laser devices. The Others segment provides information system construction and voice synthesis software.

  • Revenue in JPY (TTM)820.05bn
  • Net income in JPY195.84bn
  • Incorporated1944
  • Employees35.70k
  • Location
    Hoya Corp20F, Nittochi Nishishinjuku Bldg., 6-10-SHINJUKU-KU 160-8347JapanJPN
  • Phone+81 369114811
  • Websitehttps://www.hoya.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		7741:TYO since
announced		Transaction
value
Wassenburg Medical Devices BVDeal completed24 Nov 202324 Nov 2023Deal completed16.72%--
Data delayed at least 15 minutes, as of Nov 22 2024 06:30 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.